GLIS3 and type 2 diabetes mellitus: GLIS3 mutations have been detected in relation to neonatal, type 1, and type 2 diabetes, reflecting its function in pancreatic β-cells, where it is a drug candidate for treating a broad range of GLIS3-associated diabetic patients [67].